Uwe Kirchefer

Future GLP-1 receptor co-agonists and their cardiac effects

Agonists at glucagon-like-peptide-1 receptors (GLP-1R) are becoming approved drugs to treat not only type 2 diabetes and obesity but also cardiac diseases such as coronary heart disease, myocardial infarction and heart failure. Agonism at the GLP-1R can be combined with agonism a...